ArticleBMC gastroenterology2025
LINC00634 is a novel prognostic biomarker for colon cancer associated with immune infiltration.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColon cancer is a highly heterogeneous and most common malignant tumor of the gastrointestinal tract, which is prone to metastasis in advanced stages, leading to a poor prognosis for patients.
methodsTo gain a comprehensive understanding of genes associated with the prognosis of colon cancer, we identified a gene set (DPP7, TRPM5, ASB6, LINC00634 and GABRD) with potential prognostic value via genome-wide overall survival (OS) analysis. Further, LINC00634 was silenced by constructing small interfering RNAs (siRNAs) in Colo-320 cells.
resultsMultifactorial Cox regression analysis revealed that LINC00634, TRPM5, age, T and M stages were independent risk factors for the prognosis of colon cancer patients. Nomogram demonstrated that these risk factors had favorable predictive ability for 1-, 3- and 5-year OS in colon cancer patients. In addition, high expression of LINC00634 had a worse prognosis for colon cancer patients compared to TRPM5. In vitro experiments showed that silencing LINC00634 significantly inhibited cell proliferation and migration, and promoted cell apoptosis. Finally, immune infiltration analysis revealed that colon cancer patients with high expression of LINC00634 had lower infiltration levels of myeloid dendritic cells (mDCs) and CD8
conclusionOur study found that LINC00634 can be used as a novel prognostic and immunological marker for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.